Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


       Taj Pharmaceuticals Limited logo

Ziprasidone-Hcl Taj API

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  
Ziprasidone Hcl Manufacturers in India Suppliers Ziprasidone Hcl Exporters Distributors Ziprasidone Hcl api active pharmaceuticals ingredients Ziprasidone Hcl manufacturers Side Effects bulk drugs raw material Ziprasidone Hcl companies Side Effects Importers Ziprasidone Hcl Ziprasidone Hcl Exporters Ziprasidone Hcl exporters FDA Ziprasidone Hcl DMF Symptoms Generic Taj Pharmaceuticals Ltd. active pharmaceutical ingredients suppliers pharmaceutical Ziprasidone Hydrochloride manufacturing pharmaceutical drugs pharmaceutical intermediates Ziprasidone Hydrochloride pharmaceutical chemicals pharmaceutical raw materials Ziprasidone Hydrochloride active pharmaceutical ingredients Ziprasidone Hydrochloride committee active pharmaceutical ingredients manufacturer Ziprasidone Hydrochloride Active Pharmaceutical Ingredients manufacturer Ziprasidone Hydrochloride exporter drug ingredients pharmaceuticals Pharmaceuticals API Manufacturer Ziprasidone Hcl, Ziprasidone Hcl manufacturer India, Ziprasidone Hcl product, Ziprasidone Hcl products, Api preparation, Certificate of Analysis API manufacturer product, Ziprasidone Hcl anti ulcer product, Certificate of Origin COA Ziprasidone Hcl COS Ziprasidone Hcl, pharmaceutical generic, pharmaceutical drug, medical, Ziprasidone Hcl pharma healthcare, pharma patents, contract MSDS manufacturing Trader Ziprasidone Hcl pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Ziprasidone Hcl expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Ziprasidone Hcl DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Ziprasidone Hcl ingredients, api, HIV Ziprasidone Hcl, tablets, capsules, syrup & protein Ziprasidone Hcl powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Ziprasidone Hcl gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Ziprasidone Hcl WHO, UKMHRA Approval
   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 

taj pharma ltd. Ziprasidone-Hcl





 











 






 

 

 

 

HOME >> API >> API List 3 >> Ziprasidone Hcl >> Interaction

Ziprasidone Hcl CAS Registry Number 138982-67-9

INTERACTION

Ziprasidone Hcl CAS Registry Number 138982-67-9


The Effect of Other Drugs on Ziprasidone

Carbamazepine - Carbamazepine is an inducer of CYP3A4; administration of 200 mg BID for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. This effect may be greater when higher doses of carbamazepine are administered.

Ketoconazole - Ketoconazole, a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5 days, increased the AUC and Cmax of ziprasidone by about 35-40%. Other inhibitors of CYP3A4 would be expected to have similar effects.

Cimetidine - Cimetidine at a dose of 800 mg QD for 2 days did not affect ziprasidone pharmacokinetics.

Antacid - The coadministration of 30 mL of Maalox® with ziprasidone did not affect the pharmacokinetics of ziprasidone.

In addition, population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.
Effect of Ziprasidone on Other Drugs

Lithium - Ziprasidone at a dose of 40 mg BID administered concomitantly with lithium at a dose of 450 mg BID for 7 days did not affect the steady-state level or renal clearance of lithium.

Oral Contraceptives - Ziprasidone at a dose of 20 mg BID did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg).

Dextromethorphan - Consistent with in vitro results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.

Information Associated with Product:
DRUG DESCRIPTION
DOSAGE
SIDE EFFECTS
PRECAUTIONS
INTERACTION >>
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Ziprasidone Hcl

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited  products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.